Filtered By:
Condition: Atrial Fibrillation
Drug: Aspirin

This page shows you your search results in order of relevance. This is page number 10.

Order by Relevance | Date

Total 563 results found since Jan 2013.

Antithrombotic treatment after stroke due to intracerebral haemorrhage
CONCLUSIONS: We did not identify beneficial or hazardous effects of short-term prophylactic dose parenteral anticoagulation and long-term oral antiplatelet therapy after ICH on important outcomes. Although there was a significant reduction in MACE and all major occlusive vascular events after long-term treatment with therapeutic dose oral anticoagulation for atrial fibrillation after ICH, the pooled estimates were imprecise, the certainty of evidence was only moderate, and effects on other important outcomes were uncertain. Large RCTs with a low risk of bias are required to resolve the ongoing dilemmas about antithrombotic...
Source: Cochrane Database of Systematic Reviews - January 26, 2023 Category: General Medicine Authors: Alexia Cochrane Chen Chen Jacqueline Stephen Ole Morten R ønning Craig S Anderson Graeme J Hankey Rustam Al-Shahi Salman Source Type: research

Abstract 200: Cost-Effectiveness of Newer Anticoagulants for Stroke Prevention in Atrial Fibrillation Poster Session II
Conclusions: Cost-effectiveness models of newer anticoagulants for SPAF have been extensively published. Models have frequently found newer anticoagulants to be cost-effective, but due to the lack of head-to-head trial comparisons and heterogeneity in clinical characteristic of underlying trials and modeling methods, it is currently unclear which of these newer agents is most cost-effective.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: Limone, B. L., Baker, W. L., Coleman, C. I. Tags: Poster Session II Source Type: research

An Emergency Department Intervention to Increase Warfarin Use for Atrial Fibrillation
Conclusions: This practical stroke prevention quality improvement initiative was not associated with an increase in warfarin use among ED patients with AF.
Source: Journal of Stroke and Cerebrovascular Diseases - December 20, 2012 Category: Neurology Authors: Lesli E. Skolarus, Lewis B. Morgenstern, Phillip A. Scott, Lynda D. Lisabeth, Jillian B. Murphy, Erin M. Migda, Devin L. Brown Tags: Original Articles Source Type: research

Major Bleeding in Patients With Atrial Fibrillation Receiving Apixaban or Warfarin The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes
This study sought to characterize major bleeding on the basis of the components of the major bleeding definition, to explore major bleeding by location, to define 30-day mortality after a major bleeding event, and to identify factors associated with major bleeding.BackgroundApixaban was shown to reduce the risk of major hemorrhage among patients with atrial fibrillation in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial.MethodsAll patients who received at least 1 dose of a study drug were included. Major bleeding was defined according to the criteria of the Inte...
Source: Journal of the American College of Cardiology: Cardiovascular Interventions - May 19, 2014 Category: Cardiology Source Type: research

Left atrial appendage occlusion for stroke prevention in atrial fibrillation: multicentre experience with the AMPLATZER Cardiac Plug.
Conclusions: In this multicentre study, LAAO with the ACP showed high procedural success and a favourable outcome for the prevention of AF-related thromboembolism. Modification in antithrombotic therapy after LAAO may result in reduction of bleeding events. PMID: 25604089 [PubMed - as supplied by publisher]
Source: EuroIntervention - January 26, 2015 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research

INR optimization based on stroke risk factors in patients with non-valvular atrial fibrillation
Conclusion The intensity of anticoagulation therapy for Korean patients with NVAF is optimal when INR is between 1.7 and 2.2.
Source: International Journal of Clinical Pharmacy - June 12, 2015 Category: Drugs & Pharmacology Source Type: research

The adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation
ConclusionDOACs prescribing grew rapidly from 2013 to 2014, regionally and nationally. Warfarin prescriptions have remained stable, indicating that more patients are being appropriately anticoagulated for atrial fibrillation that previously were not. DOACs were found to be prescribed to patients with lower CHA2DS2VASc and HASBLED scores, younger age, and higher GFR. Aspirin therapy remains over utilised in AF.
Source: Internal Medicine Journal - April 3, 2016 Category: Internal Medicine Authors: David Baker, Bradley Wilsmore, Seshasayee Narasimhan Tags: Original Article Source Type: research

Amplatzer Cardiac Plug for Stroke Prevention in Patients with Atrial Fibrillation and Bigger Left Atrial Appendix Size
This study aims to evaluate the results associated with LAA closure with the Amplatzer cardiac plug (ACP, AGA, St. Jude Medical, Minneapolis, MN) in bigger LAA size. A total of 25 patients with NVAF underwent LAA closure with the ACP device. All patients received short-term (up to 3 months) dual-antiplatelet therapy (clopidogrel and aspirin) after the procedure and aspirin only thereafter. A transesophageal echocardiography was performed in all patients at the 3- and 6-month follow-ups. No patient was lost to follow-up (≥ 12 months in all patients). The mean age, CHA2DS2-VASc score, and HAS-BLED score were 66.2 ± 8....
Source: International Journal of Angiology - April 25, 2016 Category: Cardiology Authors: Yuniadi, YogaHanafy, Dicky A.Raharjo, Sunu B.Soeryo, ArioYasmina, IIfSoesanto, Amiliana M. Tags: Original Article Source Type: research

Adoption of direct oral anticoagulants for stroke prevention in atrial fibrillation
Conclusion DOAC prescribing grew rapidly from 2013 to 2014, regionally and nationally. Warfarin prescriptions have remained stable, indicating that more patients are being appropriately anticoagulated for AF who previously were not. DOAC were found to be prescribed to patients with lower CHA2DS2VASc and HAS‐BLED scores, younger age and higher glomerular filtration rates. Aspirin therapy remains over utilised in AF.
Source: Internal Medicine Journal - July 11, 2016 Category: Internal Medicine Authors: D. Baker, B. Wilsmore, S. Narasimhan Tags: Original Article Source Type: research

A Systematic Literature Review on the Cost-Effectiveness of Apixaban for Stroke Prevention in Non-valvular Atrial Fibrillation
Conclusion Different cost-effectiveness analyses suggest that apixaban is a cost-effective therapeutic option according to the WTP thresholds used in countries where cost-effectiveness analyses, were performed. Funding BMS and Pfizer.
Source: Cardiology and Therapy - July 24, 2016 Category: Cardiology Source Type: research

Atrial fibrillation: Stroke prevention in atrial fibrillation: can we do better?
Nature Reviews Cardiology 13, 511 (2016). doi:10.1038/nrcardio.2016.117 Authors: Deirdre A. Lane & Gregory Y. H. Lip Clinical guidelines advocate oral anticoagulation (OAC) for stroke prevention in patients with atrial fibrillation and ≥1 risk factors for stroke, but 40% of eligible patients receive aspirin, and those at greatest risk are least likely to be prescribed OAC. Why is there a discrepancy between guidelines and clinical practice?
Source: Nature Reviews Cardiology - July 27, 2016 Category: Cardiology Authors: Deirdre A. Lane Gregory Y. H. Lip Tags: News and Views Source Type: research

Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective
ConclusionsBased on the present analysis, apixaban represents a cost-effective treatment option versus warfarin and aspirin for the prevention of stroke in patients with AF from a Greek healthcare payer perspective over a lifetime horizon.
Source: American Journal of Cardiovascular Drugs - November 22, 2016 Category: Cardiology Source Type: research

Long ‐term aspirin does not lower risk of stroke and increases bleeding risk in low risk atrial fibrillation ablation patients
Conclusions: After catheter ablation, low risk patients do not benefit from long‐term aspirin therapy, but are at risk for higher rates of bleeding when compared to no therapy or warfarin.This article is protected by copyright. All rights reserved
Source: Journal of Cardiovascular Electrophysiology - August 1, 2017 Category: Cardiology Authors: Victoria Jacobs, Heidi T. May, Tami L. Bair, Brian G. Crandall, Michael J. Cutler DO, John D. Day, Charles Mallender, Jeffrey S. Osborn, J. Peter Weiss, T. Jared Bunch Tags: ORIGINAL ARTICLE Source Type: research

Uptake of Oral Anticoagulants for Stroke Prevention in Patients with Atrial Fibrillation in a Single Clinical Commissioning Group in England Without Restrictions to Their Use
ConclusionsThe early use of DOACs, in a CCG without restrictions to their use, was embraced by primary-care prescribers in this particular CCG.
Source: Clinical Drug Investigation - February 25, 2019 Category: Drugs & Pharmacology Source Type: research